Literature DB >> 2849043

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

W K Eng1, L Faucette, R K Johnson, R Sternglanz.   

Abstract

The budding yeast Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe are both sensitive to camptothecin, an inhibitor of DNA topoisomerase I. An S. cerevisiae DNA repair mutant, rad52, is hypersensitive to the drug. In both species, topoisomerase I mutants totally lacking the enzyme are completely resistant to the drug. A strain with a mutation leading to a temperature-sensitive topoisomerase I exhibits temperature dependence in its in vivo response to camptothecin. A strain carrying a plasmid that overproduces topoisomerase I is hypersensitive to the drug. The rad52 mutant is killed by overproduction of the enzyme, even in the absence of the drug. The response of several of these strains to camptothecin analogs, to DNA topoisomerase II inhibitors, and to other drugs is reported. The cytotoxic effects of camptothecin are discussed in terms of the drug extending the lifetime of a topoisomerase I-DNA covalent intermediate, which is recognized as DNA damage by a DNA repair system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849043

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  74 in total

1.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 3.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

4.  Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones.

Authors:  J J Champoux
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

5.  Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Thomas S Dexheimer; Shunichi Takeda; Yves Pommier
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

Review 6.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

7.  Yeast glycosylation mutants are sensitive to aminoglycosides.

Authors:  N Dean
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.

Authors:  S E Porter; J J Champoux
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

Review 9.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

10.  Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.

Authors:  J Pollina; R J Plunkett; M J Ciesielski; A Lis; T A Barone; S J Greenberg; R A Fenstermaker
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.